Overview
Although recognised as the most effective antipsychotic for treatment-resistant schizophrenia, clozapine remains underused. This session will explore the reasons behind this and describe different approaches that have been used to improve this. Thomas Barnes will describe the findings from POMH on the use of clozapine over time across UK, Emma Butler will present a naturalistic study assessing the feasibility and cost-effectiveness of community initiation of clozapine. Finally, Sebastien Brodeur will present the Robert Kerwin prize winning lecture 2023, exploring the reasons behind poor out-patient adherence to clozapine in a cohort study of patients in Quebec, Canada.
Objectives
By the end of this session, attendees will be able to:
- describe the current pattern of clozapine in clinical services in UK
- identify the reasons behind the low adherence to best practice guidelines in the use of clozapine in treatment resistant schizophrenia
- consider a range of approaches to improve the uptake of clozapine in clinical practice.
Speakers
Chair: Dr Konstantinos Ioannidis, University of Oxford, Oxford
Dr Carol Paton, Oxleas NHS Foundation Trust, Dartford
Ms Emma Butler, King's College London, London
Dr Sébastien Brodeur, Laval University, Quebec
